Core Insights - Abeona Therapeutics has received a permanent HCPCS J-code for its gene therapy ZEVASKYN, which will enhance reimbursement processes and patient access starting January 1, 2026 [1][2] Company Overview - Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [7] - ZEVASKYN (prademagene zamikeracel) is the first and only autologous cell sheet-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [3][4] Product Details - ZEVASKYN is designed to treat wounds in adult and pediatric patients suffering from RDEB, a severe skin disease caused by defects in the COL7A1 gene [3][4] - The therapy involves inserting the correct COL7A1 gene into a patient's skin cells ex vivo, leading to the production of functional type VII collagen [3] - Clinical results indicate that ZEVASKYN provides meaningful wound healing and pain reduction with a single application [3] Regulatory and Market Impact - The assignment of a unique J-code by CMS is expected to simplify claims and reimbursement processing, thereby supporting hospital adoption and patient access for ZEVASKYN [2] - J-codes are crucial for identifying non-orally administered medications in healthcare settings, streamlining medical billing and reimbursement processes [2]

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA). The approval makes Singapore the first country in Southeast Asia to fully approve the latest COVID-19 vaccine for use in individuals 6 months of age and older. The LP.8.1 sublineage was chosen based ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Equinox Gold (EQX) engages in the acquisition, exploration and development of mineral deposits. The Zacks Consensus Estimate for its current year earnings has been revised almost 26.5% downward over the last 60 days.Golden Entertainment (GDEN)  is a diverse gaming company which offers casino, distribute gaming and lottery services. The Zacks Consensus Estimate for its current year earnings has been revised 16.2% downward over the last ...

Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin healthZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined – eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovatio ...

Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call October 30, 2025 08:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchChris Schott - Managing DirectorChuck Triano - SVP and Head of Investor RelationsMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchCristian Massacesi - Chief Medical Officer and Head of Global Drug DevelopmentChris Boerner - Board Chair and CEOAdam Lenkowsky - Chief Commercialization OfficerCarter Gould - Biopharma Equity Re ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that late-breaking data demonstrating durable clinical activity of AgenT-797, allo-INKTs, in advanced solid tumors will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 7–9, 2025, in National Harb ...

BREAKING: Futures Mixed After Trump, Xi MeetAlnylam easily beat Wall Street's third-quarter forecasts on the back of its biggest moneymaker, Amvuttra. Alnylam stock, which has already doubled in 2025, could get a boost from the results.Amvuttra treats forms of transthyretin amyloidosis, a condition in which abnormal protein builds up on the organs. The Food and Drug Administration first approved Alnylam Pharmaceuticals' (ALNY) drug for patients with neuropathy in June 2022. This March, the agency signed off ...

Core Viewpoint - Aligos Therapeutics, Inc. is set to report its third quarter 2025 financial results on November 6, 2025, before the U.S. financial markets open [1] Company Overview - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing best-in-class therapies for liver and viral diseases [2] - The company aims to improve patient outcomes through a science-driven approach and deep R&D expertise [2] - Aligos has a pipeline targeting high unmet medical needs, including chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses [2]

THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at ht ...

Core Insights - Oncotelic Therapeutics Inc. is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the evolving landscape of cancer therapy through innovative drug delivery systems [1][2]. Industry Overview - The global cancer-therapy landscape is rapidly evolving towards precision drug-delivery systems aimed at enhancing efficacy, reducing toxicity, and improving patient outcomes. Traditional treatments face challenges such as low bioavailability and poor tumor targeting, which limit their clinical success [2]. - Breakthroughs in nanomedicine are addressing these challenges, with increasing support from regulatory bodies like the U.S. FDA for nanocarrier-based delivery technologies in advanced therapeutics [2][3]. Company Profile - Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications with innovative therapeutic candidates [4]. - The company utilizes its proprietary Deciparticle(TM) platform to enhance the bioavailability and therapeutic index of existing oncology drugs, potentially redefining cancer treatment standards by improving underutilized compounds [3][4]. - Oncotelic holds a 45% stake in GMP Bio, a joint venture that is advancing its own pipeline of drug candidates, further strengthening Oncotelic's strategic position in oncology and rare disease therapeutics [4].